Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neumora Therapeutics (NMRA) Depreciation & Amortization (CF) (2022 - 2026)

Neumora Therapeutics' quarterly Depreciation & Amortization (CF) came in at $8000.0 in Q1 2026, down 94.9% year-on-year from $157000.0 in Q1 2025, and down 11.11% quarter-over-quarter from $9000.0 in Q4 2025.

Neumora Therapeutics has reported Depreciation & Amortization (CF) for 5 years, with the latest figure at $8000.0 in Q1 2026.

  • For the quarter ending Q1 2026, Depreciation & Amortization (CF) fell 94.9% year-over-year to $8000.0; the trailing twelve-month figure through Mar 2026 stood at $59000.0 (down 90.63% YoY), and the FY2025 full-year result was $208000.0, down 67.04% from the prior year.
  • Depreciation & Amortization (CF) for Q1 2026 stood at $8000.0, down from $9000.0 in the prior quarter.
  • The five-year high for Depreciation & Amortization (CF) was $198000.0 in Q4 2023, with the low at $8000.0 in Q1 2026.
  • Average Depreciation & Amortization (CF) over 5 years is $121000.0, with a median of $157000.0 recorded in 2024.
  • Year-over-year, Depreciation & Amortization (CF) soared 34.69% in 2023 and plunged 94.9% in 2026.
  • Tracing NMRA's Depreciation & Amortization (CF) over 5 years: stood at $147000.0 in 2022, then surged by 34.69% to $198000.0 in 2023, then slipped by 20.71% to $157000.0 in 2024, then slumped by 94.27% to $9000.0 in 2025, then slipped by 11.11% to $8000.0 in 2026.
  • The last three Depreciation & Amortization (CF) figures came in at $8000.0 (Q1 2026), $9000.0 (Q4 2025), and $23000.0 (Q3 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Depreciation & Amortization (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - -
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - 1,395.22
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - -
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn 55.90 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn 123.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 13.55 Mn
10 Neumora Therapeutics 328.27 Mn 328.27 Mn - 8,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 8,000.00
Mar 31, 2026 8,000.00
Dec 31, 2025 9,000.00
Dec 31, 2025 9,000.00
Sep 30, 2025 23,000.00
Sep 30, 2025 23,000.00
Jun 30, 2025 19,000.00
Jun 30, 2025 19,000.00
Mar 31, 2025 157,000.00
Mar 31, 2025 157,000.00
Dec 31, 2024 157,000.00
Dec 31, 2024 157,000.00
Sep 30, 2024 156,000.00
Sep 30, 2024 156,000.00
Jun 30, 2024 160,000.00
Jun 30, 2024 160,000.00
Mar 31, 2024 158,000.00
Mar 31, 2024 158,000.00
Dec 31, 2023 198,000.00
Dec 31, 2023 198,000.00
Sep 30, 2023 173,000.00
Sep 30, 2023 173,000.00
Jun 30, 2023 171,000.00
Jun 30, 2023 171,000.00
Mar 31, 2023 158,000.00
Mar 31, 2023 158,000.00
Dec 31, 2022 147,000.00
Dec 31, 2022 147,000.00